← All organizations
BeOne Medicines
Also known as: BeiGene | BEIGENE | Beigene (Beijing) Biotechnology Co., Ltd | BeiGene (Beijing) Co., Ltd | BeiGene, Ltd. | BeiGene (Suzhou) Co., Ltd. | BeiGene USA, Inc. | BEIGENE USA INC | Beigne | BeOne Medicines | BEONE MEDICINES USA
Highest phase reached
Phase 4
First clinical trial
Nov 1, 2013First marketed drug
Nov 14, 2019First NDA
Nov 14, 2019Last known activity
May 13, 2026
Timeline
2010s
- Jun 1, 2010
BeOne Medicines— Founded
- Nov 14, 2019
zanubrutinib— Marketing Organization
- Nov 14, 2019
zanubrutinib— NDA Organization
Drugs by trial phase (124 distinct, 235 trials)
Phase 4 (1 own, 0 via acquisition)
Phase 3 (35 own, 0 via acquisition)
Phase 2 (42 own, 0 via acquisition)
Phase 1 (46 own, 0 via acquisition)
Indications
Studied for
- Adenocarcinoma
- Biliary Tract Neoplasms
- Breast Neoplasms
- Carcinoma
- Carcinoma, Hepatocellular
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Ovarian Epithelial
- Carcinoma, Renal Cell
- Carcinoma, Squamous Cell
- Carcinoma, Transitional Cell
- Central Nervous System Neoplasms
- Esophageal Neoplasms
- Esophageal Squamous Cell Carcinoma
- Glioblastoma
- Glioma
- Hepatic Insufficiency
- Hodgkin Disease
- Immunoblastic Lymphadenopathy
- Infections
- Kidney Neoplasms
- Leiomyomatosis
- Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Liver Failure
- Lung Neoplasms
- Lupus Nephritis
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, B-Cell, Marginal Zone
- Lymphoma, Extranodal NK-T-Cell
- Lymphoma, Follicular
- Lymphoma, Large B-Cell, Diffuse
- Lymphoma, Large-Cell, Anaplastic
- Lymphoma, Mantle-Cell
- Lymphoma, Non-Hodgkin
- Lymphoma, T-Cell
- Lymphoma, T-Cell, Cutaneous
- Lymphoma, T-Cell, Peripheral
- Nasopharyngeal Carcinoma
- Nasopharyngeal Neoplasms
- Neoplasms
- Nephritis
- Nervous System Neoplasms
- Ovarian Neoplasms
- Prostatic Neoplasms
- Small Cell Lung Carcinoma
- Stomach Neoplasms
- Triple Negative Breast Neoplasms
- Urinary Bladder Neoplasms
- Uterine Cervical Neoplasms
- Waldenstrom Macroglobulinemia
Marketed drugs (2)
Recent trials (50)
- NCT04052854Lead sponsorN/A—
- NCT07277231Lead sponsorPhase 3Jan 31, 2026
- NCT07277231OfficialPhase 3Jan 31, 2026
- NCT07222267OfficialPhase 1Dec 31, 2025
- NCT07222267Lead sponsorPhase 1Dec 31, 2025
- NCT07226349OfficialPhase 1Dec 2, 2025
- NCT07226349Lead sponsorPhase 1Dec 2, 2025
- NCT07205731CollaboratorPhase 2Oct 31, 2025
- NCT07296705CollaboratorPhase 2Oct 25, 2025
- NCT07181681OfficialPhase 1Oct 22, 2025
- NCT07181681Lead sponsorPhase 1Oct 22, 2025
- NCT07169331OfficialPhase 4Oct 17, 2025
- NCT07169331Lead sponsorPhase 4Oct 17, 2025
- NCT07136077CollaboratorPhase 2Sep 18, 2025
- NCT06973187OfficialPhase 3Sep 4, 2025
Details
- Founded
- Beijing, CN Jun 1, 2010
- First NDA
- Nov 14, 2019
- Last known activity
- May 13, 2026
Designations held
- Orphan drug
- Priority review
- Breakthrough therapy
- Accelerated approval
Notes
Renamed from BeiGene